Back to News
Market Impact: 0.35
Regeneron: Why I Still See Upside After The Rally
Source: seekingalpha.com
Company FundamentalsCorporate EarningsRegulation & LegislationAnalyst Insights
Regeneron’s Dupixent delivered €5.15B in Q2 sales, up 23.6% sequentially, offsetting ongoing U.S. Eylea pressure from biosimilar launches. The article notes the Eylea decline is no longer weighing on REGN shares, implying improved near-term revenue momentum driven by Dupixent growth.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
REGN0.55
More News
- Here are the 6 big things we're watching in the stock market this week
- JPMorgan Chase, Goldman and other big banks report earnings this week. What to expect
- Big Banks Face Test as Earnings Season Begins
- This Chinese memory chip maker has global potential and is poised to outperform
- Senators call on Trump to scrap diesel deal, saying U.S. ‘should not provide Putin with a financial lifeline’ while Russia kills Ukrainian civilians
- The paradox at the core of the AI revolution: The faster we innovate, the slower we grow